Drug Trial Radar · NCT06038578
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
146
Planned (sponsor's estimate)
Start
Oct 4, 2023
Primary completion
Oct 31, 2027
Study completion Oct 31, 2027
Sponsor
- Lead sponsor
- Toray Industries, IncIndustry
- Sponsor type
- Industry
- First posted
- Sep 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocarcinoma.
Conditions
- Gastric Adenocarcinoma
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
Interventions
TRK-950Biological
5 mg/kg or 10 mg/kg IV infusion over 60 minutes on Day 1, 8, 15 and 21 of each 28 day cycle
RamucirumabDrug
8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
PaclitaxelDrug
80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free Survival (PFS)Time frame: Time from date of randomization to the date of progressive disease or death due to any cause, whichever occurs first, up to approximately 24 months
Locations
27 sites in 3 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
City of Hope at Orange County Lennar Foundation Cancer Center
Irvine, California · Recruiting
University of California, Los Angeles
Santa Monica, California · Recruiting
Texas Oncology Arlington North
Arlington, Texas · Recruiting
Texas Oncology Bedford
Bedford, Texas · Recruiting
Texas Oncology Dallas Methodist
Dallas, Texas · Recruiting
Texas Oncology Dallas Medical City
Dallas, Texas · Recruiting
Texas Oncology Dallas Presbyterian
Dallas, Texas · Recruiting
Texas Oncology Methodist Charlton Cancer Center
Dallas, Texas · Recruiting
Texas Oncology-Sammons Cancer Center
Dallas, Texas · Recruiting
Texas Oncology Fort Worth Cancer Center
Fort Worth, Texas · Recruiting
Texas Oncology Grapevine
Grapevine, Texas · Recruiting
Texas Oncology Plano East
Plano, Texas · Recruiting
Texas Oncology Plano West
Plano, Texas · Recruiting
National Cancer Center Hospital
Chūōku, Japan · Recruiting
Osaka International Cancer Institute
Chūōku, Japan · Recruiting
National Cancer Center Hospital East
Kashiwa, Japan · Recruiting
The Cancer Institute Hospital of JFCR
Kōtoku, Japan · Recruiting
Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center
Yokohama, Kanagawa, Japan · Recruiting
Saitama Prefectural Hospital Organization Saitama Cancer Center
Shinden, Saitama, Japan · Recruiting
Shizuoka Cancer Center
Nagaizumi-cho, Shizuoka, Japan · Recruiting
Kyungpook National University Chilgok Hospital
Daegu, South Korea · Recruiting
Severance Hospital
Seoul, South Korea · Recruiting
ASAN Medical Center
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea · Recruiting
Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-do, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.